ArticleJACC. Case reports2026
Amyloid Light Chain Amyloidosis Involving the Heart and Temporal Arteries, Mimicking Giant Cell Arteritis.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmyloid light chain (AL) amyloidosis is an uncommon multisystem condition. We report a globally unique case of a patient with AL amyloidosis affecting the heart and temporal arteries. CASE SUMMARY: A 74-year-old man presented with jaw claudication and temporal artery tenderness and was treated for giant cell arteritis. He was later admitted to the cardiology service with elevated cardiac biomarkers with echocardiographic features of an infiltrative cardiomyopathy. Cardiac magnetic resonance suggested amyloidosis, and diagnosis of AL amyloidosis was confirmed via temporal artery biopsy. Treatment with bortezomib, cyclophosphamide, and dexamethasone yielded an appropriate clinical response. DISCUSSION: Although AL amyloidosis is known to be associated with cardiac involvement with isolated cases of large vessel involvement, this is the first global case to our knowledge of AL amyloid affecting the temporal arteries and cardiac function simultaneously. TAKE-HOME MESSAGES: AL amyloidosis is a multisystem disorder. Cardiac phenotyping should be mandatory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.